These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 32022615)

  • 21. Fewer tumour-specific PD-1
    Xu K; Fu Y; Han Y; Xia R; Xu S; Duan S; Zhang Z; Li J
    Br J Cancer; 2020 Sep; 123(6):932-941. PubMed ID: 32616847
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expansion of tumor-infiltrating lymphocytes from head and neck squamous cell carcinoma to assess the potential of adoptive cell therapy.
    Choi S; Hossain M; Lee H; Baek J; Park HS; Lim CL; Han D; Park T; Kim JH; Gong G; Kweon MN; Lee HJ
    Cancer Immunol Immunother; 2024 Apr; 73(6):101. PubMed ID: 38630265
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumour infiltrating lymphocytes in oropharyngeal carcinoma: prognostic value and evaluation of a standardised method.
    De Keukeleire SJ; Vermassen T; De Meulenaere A; Deron P; Huvenne W; Duprez F; Creytens D; Van Dorpe J; Rottey S; Ferdinande L
    Pathology; 2021 Dec; 53(7):836-843. PubMed ID: 34217516
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The prognostic significance of tumor-infiltrating lymphocytes assessment with hematoxylin and eosin sections in resected primary lung adenocarcinoma.
    Kim A; Lee SJ; Ahn J; Park WY; Shin DH; Lee CH; Kwon H; Jeong YJ; Ahn HY; I H; Kim YD; Cho JS
    PLoS One; 2019; 14(11):e0224430. PubMed ID: 31743333
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comprehensive analysis of immune cell enrichment in the tumor microenvironment of head and neck squamous cell carcinoma.
    Mito I; Takahashi H; Kawabata-Iwakawa R; Ida S; Tada H; Chikamatsu K
    Sci Rep; 2021 Aug; 11(1):16134. PubMed ID: 34373557
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Telltale tumor infiltrating lymphocytes (TIL) in oral, head & neck cancer.
    Lei Y; Xie Y; Tan YS; Prince ME; Moyer JS; Nör J; Wolf GT
    Oral Oncol; 2016 Oct; 61():159-65. PubMed ID: 27553942
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differences in TCR repertoire and T cell activation underlie the divergent outcomes of antitumor immune responses in tumor-eradicating versus tumor-progressing hosts.
    Woolaver RA; Wang X; Krinsky AL; Waschke BC; Chen SMY; Popolizio V; Nicklawsky AG; Gao D; Chen Z; Jimeno A; Wang XJ; Wang JH
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33414263
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immune-scoring in head and neck squamous cell carcinoma: a scoping review.
    Zamani R; Rezaei N
    Expert Rev Clin Immunol; 2024 Aug; 20(8):1009-1017. PubMed ID: 37750738
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of Immune Subtypes for Predicting the Prognosis of Patients in Head and Neck Squamous Cell Carcinoma.
    Sun J; Fang G; Zuo Z; Yu X; Xue L; Li C; Li S
    Technol Cancer Res Treat; 2021; 20():15330338211045823. PubMed ID: 34657509
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Histologic pattern of invasion and epithelial-mesenchymal phenotype predict prognosis in squamous carcinoma of the head and neck.
    Wolf GT; Winter W; Bellile E; Nguyen A; Donnelly CR; McHugh JB; Thomas D; Amlani L; Rozek L; Lei YL;
    Oral Oncol; 2018 Dec; 87():29-35. PubMed ID: 30527240
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor infiltrating lymphocytes and survival in patients with head and neck squamous cell carcinoma.
    Nguyen N; Bellile E; Thomas D; McHugh J; Rozek L; Virani S; Peterson L; Carey TE; Walline H; Moyer J; Spector M; Perim D; Prince M; McLean S; Bradford CR; Taylor JM; Wolf GT;
    Head Neck; 2016 Jul; 38(7):1074-84. PubMed ID: 26879675
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis.
    Yang WF; Wong MCM; Thomson PJ; Li KY; Su YX
    Oral Oncol; 2018 Nov; 86():81-90. PubMed ID: 30409325
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High expression of CLEC10A in head and neck squamous cell carcinoma indicates favorable prognosis and high-level immune infiltration status.
    Zou M; Wu H; Zhou M; Xiao F; Abudushalamu G; Yao Y; Zhao F; Gao W; Yan X; Fan X; Wu G
    Cell Immunol; 2022 Feb; 372():104472. PubMed ID: 35093731
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessing the prognostic value of tumor-infiltrating CD57+ cells in advanced stage head and neck cancer using QuPath digital image analysis.
    de Ruiter EJ; Bisheshar SK; de Roest RH; Wesseling FWR; Hoebers FJP; van den Hout MFCM; Leemans CR; Brakenhoff RH; de Bree R; Terhaard CHJ; Willems SM
    Virchows Arch; 2022 Aug; 481(2):223-231. PubMed ID: 35451620
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research.
    Hendry S; Salgado R; Gevaert T; Russell PA; John T; Thapa B; Christie M; van de Vijver K; Estrada MV; Gonzalez-Ericsson PI; Sanders M; Solomon B; Solinas C; Van den Eynden GGGM; Allory Y; Preusser M; Hainfellner J; Pruneri G; Vingiani A; Demaria S; Symmans F; Nuciforo P; Comerma L; Thompson EA; Lakhani S; Kim SR; Schnitt S; Colpaert C; Sotiriou C; Scherer SJ; Ignatiadis M; Badve S; Pierce RH; Viale G; Sirtaine N; Penault-Llorca F; Sugie T; Fineberg S; Paik S; Srinivasan A; Richardson A; Wang Y; Chmielik E; Brock J; Johnson DB; Balko J; Wienert S; Bossuyt V; Michiels S; Ternes N; Burchardi N; Luen SJ; Savas P; Klauschen F; Watson PH; Nelson BH; Criscitiello C; O'Toole S; Larsimont D; de Wind R; Curigliano G; André F; Lacroix-Triki M; van de Vijver M; Rojo F; Floris G; Bedri S; Sparano J; Rimm D; Nielsen T; Kos Z; Hewitt S; Singh B; Farshid G; Loibl S; Allison KH; Tung N; Adams S; Willard-Gallo K; Horlings HM; Gandhi L; Moreira A; Hirsch F; Dieci MV; Urbanowicz M; Brcic I; Korski K; Gaire F; Koeppen H; Lo A; Giltnane J; Rebelatto MC; Steele KE; Zha J; Emancipator K; Juco JW; Denkert C; Reis-Filho J; Loi S; Fox SB
    Adv Anat Pathol; 2017 Sep; 24(5):235-251. PubMed ID: 28777142
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of Tobacco Smoking on the Tumor Immune Microenvironment in Head and Neck Squamous Cell Carcinoma.
    de la Iglesia JV; Slebos RJC; Martin-Gomez L; Wang X; Teer JK; Tan AC; Gerke TA; Aden-Buie G; van Veen T; Masannat J; Chaudhary R; Song F; Fournier M; Siegel EM; Schabath MB; Wadsworth JT; Caudell J; Harrison L; Wenig BM; Conejo-Garcia J; Hernandez-Prera JC; Chung CH
    Clin Cancer Res; 2020 Mar; 26(6):1474-1485. PubMed ID: 31848186
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intratumoral CD103
    Ren S; Lan T; Wu F; Chen S; Jiang X; Huo C; Li Z; Xie S; Wu D; Wang R; Li Y; Qiu L; Huang G; Li S; Wang X; Cen M; Cai T; Lin Z; Li J; Li B
    Cancer Commun (Lond); 2023 Oct; 43(10):1143-1163. PubMed ID: 37658605
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma.
    Hirata-Nozaki Y; Ohkuri T; Ohara K; Kumai T; Nagata M; Harabuchi S; Kosaka A; Nagato T; Ishibashi K; Oikawa K; Aoki N; Ohara M; Harabuchi Y; Uno Y; Takei H; Celis E; Kobayashi H
    J Transl Med; 2019 Jun; 17(1):207. PubMed ID: 31221178
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of Tumor Microenvironments between Primary Tumors and Lymph Node Metastases in Head and Neck Squamous Cell Carcinoma and Their Predictive Role in Immune Checkpoint Inhibitor Treatment.
    Kim DH; Ahn JS; Kang M; Park G; Lim Y; Hwang S; Ock CY; Koh J; Chung EJ; Kwon SK; Jeon YK; Jung KC; Ahn SH; Keam B
    Cells; 2024 Sep; 13(18):. PubMed ID: 39329741
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CD45RO+TILs: cellular biomarkers for larynx squamous cell carcinoma outcome.
    Mohammadi Y; Ahmadvand S; Mirtalebi M; Ashraf MJ; Khademi B; Ghaderi A
    Braz J Otorhinolaryngol; 2022; 88 Suppl 4(Suppl 4):S133-S142. PubMed ID: 36319566
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.